These genomic differences may play a role not only in tumor location but also in therapeutic response: most of the ongoing phase III clinical trials on therapeutic strategies for iCCA are testing specific agents targeting IDH-mutated CCA (NCT02989857) and FGFR2 fusion-positive CCA (NCT03773302) [33,34]. This evidence concerns the gene FGFR2 and neoplasm.